In consequence, as recombinant PAPP-A2 is currently unavailable for treatment, rhIGF1 should be considered a safe and effective therapy in patients with PAPP-A2 deficiency to increase their growth and BMD, especially during childhood and puberty. Here, PAPPA2 is linked to hyperinsulinemic hypoglycemia, familial, 4.